Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Hypertension | Study protocol

Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD

Authors: Keith C. Norris, O. Kenrik Duru, Radica Z. Alicic, Kenn B. Daratha, Susanne B. Nicholas, Sterling M. McPherson, Douglas S. Bell, Jenny I. Shen, Cami R. Jones, Tannaz Moin, Amy D. Waterman, Joshua J. Neumiller, Roberto B. Vargas, Alex A. T. Bui, Carol M. Mangione, Katherine R. Tuttle, on behalf of the CURE-CKD investigators

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Chronic kidney disease (CKD) is a global public health problem, exhibiting sharp increases in incidence, prevalence, and attributable morbidity and mortality. There is a critical need to better understand the demographics, clinical characteristics, and key risk factors for CKD; and to develop platforms for testing novel interventions to improve modifiable risk factors, particularly for the CKD patients with a rapid decline in kidney function.

Methods

We describe a novel collaboration between two large healthcare systems (Providence St. Joseph Health and University of California, Los Angeles Health) supported by leadership from both institutions, which was created to develop harmonized cohorts of patients with CKD or those at increased risk for CKD (hypertension/HTN, diabetes/DM, pre-diabetes) from electronic health record data.

Results

The combined repository of candidate records included more than 3.3 million patients with at least a single qualifying measure for CKD and/or at-risk for CKD. The CURE-CKD registry includes over 2.6 million patients with and/or at-risk for CKD identified by stricter guide-line based criteria using a combination of administrative encounter codes, physical examinations, laboratory values and medication use. Notably, data based on race/ethnicity and geography in part, will enable robust analyses to study traditionally disadvantaged or marginalized patients not typically included in clinical trials.

Discussion

CURE-CKD project is a unique multidisciplinary collaboration between nephrologists, endocrinologists, primary care physicians with health services research skills, health economists, and those with expertise in statistics, bio-informatics and machine learning. The CURE-CKD registry uses curated observations from real-world settings across two large healthcare systems and has great potential to provide important contributions for healthcare and for improving clinical outcomes in patients with and at-risk for CKD.
Literature
1.
go back to reference Murphy SL, Kochanek KD, Xu JQ, Heron M. Deaths: Final data for 2012. National vital statistics reports; vol 63 no 9. Hyattsville: National Center for Health Statistics; 2015. Murphy SL, Kochanek KD, Xu JQ, Heron M. Deaths: Final data for 2012. National vital statistics reports; vol 63 no 9. Hyattsville: National Center for Health Statistics; 2015.
2.
go back to reference United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017. United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017.
11.
go back to reference Kimmel PL, Fwu CW, Abbott KC, Ratner J, Eggers PW. Racial disparities in poverty account for mortality differences in US Medicare beneficiaries. SSM - Population Health. 2016;2:123–9.CrossRef Kimmel PL, Fwu CW, Abbott KC, Ratner J, Eggers PW. Racial disparities in poverty account for mortality differences in US Medicare beneficiaries. SSM - Population Health. 2016;2:123–9.CrossRef
20.
go back to reference Nichols GA, Desai J, Elston Lafata J, Lawrence JM, O'Connor PJ, Pathak RD, et al. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis. 2012;9:E110.PubMedPubMedCentral Nichols GA, Desai J, Elston Lafata J, Lawrence JM, O'Connor PJ, Pathak RD, et al. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis. 2012;9:E110.PubMedPubMedCentral
21.
go back to reference Tuttle KR, Alicic RZ, Kenrik Duru O, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, Norris KC. Clinical Characteristics and Risk Factors for Chronic Kidney Disease among Adults and Children: An Analysis from the CURE-CKD Registry. JAMA Network Open. Tuttle KR, Alicic RZ, Kenrik Duru O, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, Norris KC. Clinical Characteristics and Risk Factors for Chronic Kidney Disease among Adults and Children: An Analysis from the CURE-CKD Registry. JAMA Network Open.
29.
go back to reference Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18(3):960–6.CrossRef Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18(3):960–6.CrossRef
35.
go back to reference Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRef Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRef
37.
go back to reference Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–37.CrossRef Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–37.CrossRef
39.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248. https://doi.org/10.1016/j.jacc.2017.11.006 Epub 2017 Nov 13. Erratum in: J Am Coll Cardiol. 2018 May 15;71(19):2275–2279.CrossRefPubMed Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248. https://​doi.​org/​10.​1016/​j.​jacc.​2017.​11.​006 Epub 2017 Nov 13. Erratum in: J Am Coll Cardiol. 2018 May 15;71(19):2275–2279.CrossRefPubMed
41.
go back to reference Lipworth L, Abdel-Kader K, Morse J, Stewart TG, Kabagambe EK, Parr SK, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016;17(1):189.CrossRef Lipworth L, Abdel-Kader K, Morse J, Stewart TG, Kabagambe EK, Parr SK, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016;17(1):189.CrossRef
44.
go back to reference Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.CrossRef Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.CrossRef
51.
go back to reference Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–28.CrossRef Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–28.CrossRef
Metadata
Title
Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD
Authors
Keith C. Norris
O. Kenrik Duru
Radica Z. Alicic
Kenn B. Daratha
Susanne B. Nicholas
Sterling M. McPherson
Douglas S. Bell
Jenny I. Shen
Cami R. Jones
Tannaz Moin
Amy D. Waterman
Joshua J. Neumiller
Roberto B. Vargas
Alex A. T. Bui
Carol M. Mangione
Katherine R. Tuttle
on behalf of the CURE-CKD investigators
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1558-9

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.